{"id":"W4290851731","doi":"10.1016/j.jtct.2022.08.010","title":"The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Miltenyi Biotec; Kite Pharma; Division of Cancer Prevention, National Cancer Institute; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb; National Cancer Institute; AbbVie; Merck; Roche; Astellas Pharma US; Amgen","keywords":"Medicine; Chemoimmunotherapy; Cost effectiveness; Quality-adjusted life year; Clinical trial; Oncology; Internal medicine; Lymphoma; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00597906,0.0009553559,0.001334228,0.0006035307,0.0001853301,0.001587135,0.0008307247,0.001125555,0.002620145],"category_scores_gemma":[0.01095671,0.0003703432,0.003157597,0.0006065192,0.0004641349,0.001065878,0.0006982996,0.00168862,0.0001360546],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003322249,"about_ca_system_score_gemma":0.001820593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005329265,"about_ca_topic_score_gemma":0.004090818,"domain_scores_codex":[0.9973437,0.002278193,0.00006933293,0.00009798783,0.0001049532,0.0001058625],"domain_scores_gemma":[0.996768,0.002477048,0.0003638383,0.00006336071,0.00008796756,0.0002398718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.1900209,0.0026062,0.02670784,0.00423786,0.01409002,0.0007786154,0.0001654864,0.658929,0.00134362,0.01035535,0.007168497,0.08359668],"study_design_scores_gemma":[0.06574977,0.02715612,0.01974383,0.002214421,0.01644424,0.0007384432,0.0003926183,0.8459519,0.001446495,0.01147185,0.008525525,0.0001648117],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9547879,0.02661355,0.004397359,0.003445704,0.0002369793,0.000950626,0.003495799,0.0000689736,0.006003072],"genre_scores_gemma":[0.996137,0.001478486,0.0007824403,0.0002576103,0.00001872,0.0002160227,0.000797944,0.000005941364,0.0003057506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00597906,"threshold_uncertainty_score":0.03162068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0411253268733812,"score_gpt":0.3165985277671497,"score_spread":0.2754732008937685,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}